Loading
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Previous close
$2.45
+$0.03 · +1.24%
Regular session · ET · Market data may be delayed.
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Day range
Current $2.45
52-week range
Current $2.45
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
68
Bullish
Risk
66
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Day range
Current $2.45
52-week range
Current $2.45
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.98M USD | 11.2M USD | −2.85M USD | 500K USD | 16.14M USD |
| Cost of goods sold | 8.58M USD | — | 10.18M USD | 8.56M USD | 7.67M USD |
| Gross profit | −6.61M USD | 11.2M USD | −13.03M USD | −8.06M USD | 8.48M USD |
| Research and development | — | 7.35M USD | — | — | — |
| Selling, general, and administrative | 3.76M USD | 5M USD | 4.9M USD | 4.06M USD | 5.33M USD |
| Operating expenses | 3.76M USD | 12.35M USD | 4.9M USD | 4.06M USD | 5.33M USD |
| Interest income | 744.07K USD | 1.15M USD | 1.37M USD | 572.58K USD | 67.7K USD |
| Interest expense | — | — | — | 27.1K USD | 203.29K USD |
| Depreciation and amortization | 60.78K USD | 41.11K USD | 28.66K USD | 9.45K USD | 380 USD |
| Operating income | −10.37M USD | −1.16M USD | −17.93M USD | −12.12M USD | 3.15M USD |
| Net income | −9.63M USD | 8.35K USD | −16.35M USD | −10.76M USD | −634.4K USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.00
144.90% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 12, 2023 | 1:17 | — | — |
Effective May 12, 2023
1:17
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI302.68K0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF186.67K0.00%93.7B USD0.05%$242.66+0.14%
Dimensional - US Small Cap ETFDFAS14.79K0.00%15.67B USD0.26%$82.20+0.18%
Dimensional - US Sustainability Core 1 ETFDFSU12.69K0.00%2.43B USD0.15%$48.42-0.39%
Dimensional - US Core Equity 1 ETFDCOR12.53K0.00%3.56B USD0.14%$84.83-0.20%
U.S. Micro Cap Portfolio ETFDFMC12.2K0.00%7.98B USD0.43%$60.36+0.60%
Dimensional - US Core Equity 2 ETFDFAC11.66K0.00%49.56B USD0.17%$45.72-0.09%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASDimensional - US Sustainability Core 1 ETFDFSUDimensional - US Core Equity 1 ETFDCORU.S. Micro Cap Portfolio ETFDFMCDimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
